Neoadjuvant nivolumab improves EFS in resectable lung cancer
Click Here to Manage Email Alerts
The addition of nivolumab to neoadjuvant chemotherapy followed by adjuvant nivolumab extended EFS among patients with resectable non-small cell lung cancer, according to the agent’s manufacturer.
Nivolumab (Opdivo, Bristol Myers Squibb) — a PD-1 immune checkpoint inhibitor — is approved in the United States for several oncology indications.
The randomized phase 3 CheckMate -77T trial included 452 patients with resectable stage IIA to stage IIIB NSCLC.
Researchers randomly assigned patients to neoadjuvant chemotherapy plus nivolumab or placebo. After surgery, patients received their assigned regimen — nivolumab or placebo — in the adjuvant setting.
The study met its primary endpoint, with results of a prespecified interim analysis showing longer EFS among patients assigned nivolumab. The trial is continuing to allow for assessment of OS, one of the study’s secondary endpoints.
The nivolumab regimen exhibited a safety profile consistent with that observed in prior studies.
Full results from CheckMate -77T will be submitted for presentation at a medical meeting, according to a Bristol Myers Squibb press release.
Collapse
Press Release
Read more about
Click Here to Manage Email Alerts